English

Research and Development

SSI is one of Denmark’s largest research institutions in the health sector.
More about SSI's research and development

R and DSSI is one of Denmark’s largest research institutions in the health sector
ProductsVaccines, In vitro diagnostics
Contract ServicesSSI provides contract work within our core activities and competences
Job and CareerRead about SSI as a workplace and meet some of our employees
SSI Diagnostica products

Order your in vitro diagnostic products online

SSI Diagnostica offers the opportunity for our direct customers to order in vitro diagnostic products online. Click here to visit the webshop…
Bandim Health Project

New Center of Excellence at SSI

The new research center - established by the Danish National Research Foundation - is led by Christine Stabell Benn. The goal is to increase understanding of the immune system. More on Center for Non-Specific Effects of Health Interventions (CENSEI)
Genetic differences helps to explain why Europeans experience higher malaria mortality than Africans
26-01-2012
It has long been known that ethnic Europeans have a much higher risk of dying from serious malaria infection than ethnic Af...
Shigellosis 2008-2010
25-01-2012
Monitoring of shigellosis in Denmark is important as it contributes to the investigation of outbreaks and the initiation of...
SSI Laboratory appointed as WHO Supranational TB Reference Laboratory
23-01-2012
The International Reference Laboratory of Mycobacteriology, under SSI’s Sector for Microbiology and Diagnostics, has been a...
Conjugate pneumococcal vaccine approved for adults over 50 years
17-01-2012
The 13-valent conjugate pneumococcal vaccine (Prevenar 13®) has been approved by the EMA (the European Medicines Agency) fo...

More news...

EPI-NEWS, No 3 - 2012
Shigellosis 2008-2010
EPI-NEWS, No 2 - 2012
Conjugate pneumococcal vaccine approved for use in adults above 50 yearsEurosurveillance fifteen year anniversary 1996-2011...
EPI-NEWS, No 1 - 2012
Infectious diseases 2011
EPI-NEWS, No 50 - 2011
Tuberculosis 2010, part II
EPI-NEWS, No 49 - 2011
Tuberculosis 2010, part I

More EPI-NEWS...

Genetic differences helps to explain why Europeans experience higher malaria mortality than Africans
26-01-2012
It has long been known that ethnic Europeans have a much higher risk of dying from serious malaria infection than ethnic Africans. Ne...
Intercell and Statens Serum Institut (SSI) progress vaccine clinical development to fight Tuberculosis
11-01-2012
The combination of SSI’s novel tuberculosis subunit vaccine candidate and Intercell’s proprietary IC31® adjuvant enters Phase II clin...
Is endometriosis associated with inflammatory bowel disease?
20-12-2011
In a nationwide Danish study published in the international journal ‘Gut’, researchers from Statens Serum Institut report that women...
Patients with severe muscular dystropy have increased risk of developing cancer
14-12-2011
Compared with the general population, patients with the disease myotonic muscular dystrophy (MMD; a form of muscular dystrophy charac...

More R and D News...

Result-oriented Business Development Manager with exceptional drive
Deadline for application: 01-02-2012
Division of Vaccine at Statens Serum Institut (SSI) is seeking an experienced and highly motivated Business Development Manager to join t...

Read more about working at SSI.

Statens Serum Institut

5, Orestads Boulevard

DK 2300 Copenhagen S

Tel.: +45 3268 3268

Fax: +45 3268 0000